Compare AVT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVT | IMVT |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.5B |
| IPO Year | 1994 | 2019 |
| Metric | AVT | IMVT |
|---|---|---|
| Price | $92.38 | $29.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 17 |
| Target Price | ★ $106.25 | $48.88 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | ★ 45.82 | N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $27,632,683,000.00 | N/A |
| Revenue This Year | $34.12 | N/A |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | $23.27 | ★ N/A |
| Revenue Growth | ★ 24.47 | N/A |
| 52 Week Low | $44.25 | $21.43 |
| 52 Week High | $108.63 | $45.42 |
| Indicator | AVT | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 40.63 |
| Support Level | $83.82 | $25.83 |
| Resistance Level | $95.26 | $29.83 |
| Average True Range (ATR) | 2.99 | 1.11 |
| MACD | -0.40 | 0.42 |
| Stochastic Oscillator | 46.26 | 73.73 |
Avnet Inc is an electronic component technology distributor and solutions provider serving customers across the Americas, EMEA, and Asia. It works with electronic component manufacturers in every electronic component segment and serves startups, mid-sized businesses, enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). Its segments are Electronic Components (EC) and Farnell, with EC generating maximum revenue. The EC operating group mainly supports high- and medium-volume customers and markets, and sells and distributes semiconductors, IP&E components (interconnect, passive, and electromechanical components), and other integrated and embedded components.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.